AMD Stock Insider Buys $1M Worth of Shares. Is This a Bullish Turning Point?
A massive insider purchase just hit Advanced Micro Devices (AMD), and it's raising eyebrows across Wall Street.
Philip Guido, AMD's Chief Commercial Officer, bought nearly $1 million worth of AMD shares on May 20, marking the stock's largest insider buy since November 2006. Insider activity like this is often seen as a signal of confidence — especially when it's this large.
While AMD is still trading about 39% off its 52-week highs, it has quietly outperformed over the past 3 months, gaining 13.8% while the broader market slipped.
Here's Why Traders Are Taking Notice
Barchart just triggered a bullish 20/100-day moving average crossover for AMD on May 27
The stock's put/call open interest ratio is falling, which may suggest bullish accumulation
AMD is gearing up for a June 12 AI event hosted by CEO Lisa Su, highlighting new developments in artificial intelligence
Even politicians like Marjorie Taylor Greene and Ro Khanna are buying the dip
Add it all up, and it's clear that AMD is becoming a key stock to watch in the AI semiconductor subsector heading into the summer.
Get the full breakdown in this news reel on AMD:
Want to track trade setups like this as they happen? Try a free 30-day trial of Barchart Premier and unlock full access to options flow, trading signals, and P&L tools.
Start Your Free Trial >>
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
Cunard's Transatlantic Fashion Week Returns With Fashion Icons Christian Siriano, Bob Mackie and Coco Rocha
The week-long voyage aboard Queen Mary 2 will feature a Siriano runway show and exclusive Mackie auction plus workshops with Supermodel Coco Rocha VALENCIA, Calif. , June 4, 2025 /CNW/ -- Cunard's Transatlantic Fashion Week voyage will sail from the U.S. for the first time this fall aboard the iconic Queen Mary 2 . The week-long voyage will feature an extraordinary line-up of fashion icons including legendary fashion designers Christian Siriano and Bob Mackie and supermodel Coco Rocha. Cunard's sails from New York to Southampton, England aboard the world's only ocean cruise liner, Queen Mary 2. From October 31 – November 7, 2025 , guests will be immersed in a unique celebration of creativity, craftsmanship and couture, all with Cunard's luxurious white star service. "Transatlantic Fashion Week has become a must-attend event since its launch in 2016, welcoming legendary designers from around the world to showcase their designs aboard the industry's most iconic ships," said Katie McAlister , President of Cunard. "The 2025 Transatlantic Fashion Week will once again embark from New York , the fashion capital of the U.S., and continues Cunard's legacy of bringing high culture to the high seas." Transatlantic Fashion Week 2025 Highlights CFDA Designer Christian Siriano will headline the voyage with his first-ever runway show at sea, presenting highlights from his celebrated 16-year archive in the ship's Queens Room. The TIME100 honoree, whose custom designs have been exhibited in museums around the world and worn by everyone from Oprah to Julia Roberts , Angelina Jolie , Halle Berry , Zendaya, Ariana Grande , Billy Porter , Lady Gaga, and Michelle Obama , will debut a one-of-a-kind nautical-themed dress, designed exclusively for Cunard and displayed throughout the voyage. Fashion lovers will also enjoy an intimate Q&A with Siriano in the Royal Court Theatre and have the opportunity to meet him during book signings. "I am honored to headline the return of Transatlantic Fashion Week and partner with a brand that has such a longstanding history with the fashion industry and its icons," said Siriano. "The new custom piece I'll be unveiling on board draws inspiration from the sea and celebrates classic glamour synonymous with Cunard." Fashion and costume design legend Bob Mackie, whose creations have been worn by stars like Cher, Diana Ross, Miley Cyrus and Madonna, will display pieces specially selected from his personal archive onboard the voyage. This includes celebrity gowns and pieces from his couture runway collections. Some Bob Mackie sketches will also be up for auction. In addition, guests will be treated to a special screening of his new documentary " Bob Mackie : Naked Illusion," which will be followed by a live Q&A with the designer himself. " I've always believed fashion should be fabulous and a bit fearless, and a ship as glamorous as Queen Mary 2 offers the perfect setting to showcase these designs and connect with fellow fashion lovers," said Bob Mackie . Accompanying Siriano and Mackie is supermodel, advocate, and entrepreneur Coco Rocha, offering guests unique insight into her 20-year career in the fashion industry. Having graced over 100 magazine covers, she's been shot by the world's top photographers and walked runways for fashion houses ranging from Chanel, Louis Vuitton , John Galliano, and Prada to Jean Paul Gaultier , Armani, and Marc Jacobs . Rocha will lead a series of workshops including a taste of the very first Coco Rocha Model Camp at sea, where the "Queen of Pose" will dive into her dynamic posing techniques which she's taught across the globe. Also joining the voyage are award-winning podcast host, fashion journalist and bestselling author Dana Thomas and brand ambassador, creative director and TV host James Aguiar , who is curating the voyage alongside Cunard. For more information about Cunard or to book a voyage, travelers can contact their Travel Advisor, call Cunard at 1-800-728-6273, or visit For Travel Advisors interested in further information, please contact your Business Development Manager, visit or call Cunard at 1-800-528-6273. About Cunard Cunard is a luxury British cruise line, renowned for creating unforgettable experiences around the world. Cunard has been a leading operator of passenger ships since 1840, and this year celebrates an incredible 185 years of operation. 2025 is a momentous year in Cunard's history, which will be marked with several iconic land-based events and special Event Voyages. The Cunard experience is built on fine dining, hand-selected entertainment, and outstanding White Star service. From a partnership with a two-Michelin starred chef, to inspiring guest speakers, to world class theatre productions, every detail has been meticulously crafted to make the experience unforgettable. A pioneer in transatlantic journeys and round world voyages, destinations sailed to also include Europe , the Caribbean , Alaska , the Far East and Australia . There are currently four Cunard ships, Queen Mary 2, Queen Elizabeth , Queen Victoria and new ship, Queen Anne , which entered service in May 2024 . This investment is part of the company's ambitious plans for the future of Cunard globally, with the brand now boasting four ships in simultaneous service for the first time since 1999. Cunard is based at Carnival House in Southampton and has been owned since 1998 by Carnival Corporation & plc. (NYSE/LSE: CCL; NYSE:CUK). SOURCE Cunard
Globe and Mail
33 minutes ago
- Globe and Mail
This BlackRock ETF Could Soar 12,400%, According to Billionaire Michael Saylor
With nearly $12 trillion in assets under management, BlackRock is one of the world's largest investment firms. As a result of its scale, it has introduced numerous exchange-traded funds (ETFs) to the market. Perhaps none have been more successful in such a short period of time than one that was launched early in 2024. Investors that are bullish on its underlying asset should be extremely intrigued. In fact, one prominent billionaire's forecast implies that this BlackRock ETF could soar 12,400% during the next 20 years. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Bullish on Bitcoin In the past decade, Bitcoin has soared 46,760% (as of June 2). This likely makes it the single-best-performing asset during that time. Today, its price sits at about $106,000, not too far off its record high of $112,000 reached last month. Michael Saylor, the co-founder and executive chairman of MicroStrategy, now called Strategy, who has a net worth estimated to be $9.4 billion, believes the party is far from finished. His base-case view is that by 2045, one Bitcoin will be worth an astonishing $13 million. Based on Bitcoin's current price, this implies 125-fold upside. The analysis is quite simple. Saylor's view is that more of the world's wealth, particularly money that today might be stored in real estate, bonds, or stocks, will flow to Bitcoin. That base-case scenario expects 7% of global assets in Bitcoin. A more bullish situation has 22% Bitcoin penetration, with a monster price target of $49 million. The bearish outlook is also quite positive -- with just 2% of assets in Bitcoin, Saylor thinks a worst-case outcome is a $3 million price tag by 2045. It doesn't matter what your perspective is with regard to what price Bitcoin will hit one day. It's very difficult, if not impossible, to correctly forecast something so precise that far in the future. What matters right now is whether you are bullish on Bitcoin. Saylor obviously is. He completely upended his company's operations by transforming it into a Bitcoin holding entity in 2020. Today, Strategy owns more than 580,000 Bitcoin units, making it by far the biggest corporate holder. It's all about convenience In January 2024, the Securities and Exchange Commission approved the launch of spot Bitcoin ETFs. The one that has amassed the most assets is BlackRock's iShares Bitcoin Trust (NASDAQ: IBIT). The ETF owns Bitcoin, and its objective is to track the cryptocurrency's price movements. There are benefits to owning this ETF. Investors can buy and sell it directly within their traditional brokerage accounts; there is no need to figure out self-custody solutions or open up a crypto-specific account and wallet. This can be ideal for those who have zero interest in learning how to do these things. The iShares Bitcoin Trust can be particularly appealing to larger pools of capital, like hedge funds, asset managers, pension funds, and sovereign wealth funds. These entities often have specific mandates restricting what kinds of assets they are allowed to invest in. While they might not be allowed to buy Bitcoin directly, owning this ETF could be an option to gain exposure. It's a regulatory-friendly way to bet on Bitcoin. The cost is low, too. The iShares Bitcoin Trust carries an expense ratio of just 0.25%. Over time, investors in this ETF keep more of their money -- a winning outcome. Saylor's base 2045 price target of $13 million for Bitcoin essentially implies a similar 12,400% gain for the iShares Bitcoin Trust. Investors who are interested in the billionaire's perspective should first and foremost take the time to learn more about Bitcoin before putting any money to work. Should you invest $1,000 in iShares Bitcoin Trust right now? Before you buy stock in iShares Bitcoin Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and iShares Bitcoin Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor 's total average return is987% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
33 minutes ago
- Globe and Mail
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla. , June 4, 2025 /CNW/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina -based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis —this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan , PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill . In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Jen Jen Yeh , MD , a surgical oncologist and professor at UNC-Chapel Hill with joint appointments in Surgery and Pharmacology. She serves as assistant dean of translational research in UNC School of Medicine and associate director of translational research in UNC Lineberger Comprehensive Cancer Center. Dr. Yeh is widely recognized for her expertise in pancreatic cancer and translational oncology. Joseph DeSimone , PhD , an award-winning chemist, entrepreneur, and academic, currently serving as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University . He is globally known for his breakthroughs in materials science, nanomedicine, and advanced manufacturing, including 3D printing. Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers , Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity Biosciences Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL ; Houston, TXRaleigh, NC ; and Torino, Italy , the company focuses on combination drug-device platforms for chronic and complex conditions. Visit:
